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The Canadian Regenerative Medicine and 
Nanomedicine Enterprise (CARMENE)
A framework for nanomedicine in Canada
In October of 2002, the Honorable Anne McLellan, Minister of Health endorsed the 
Bone and Joint Decade (2000–2010) on behalf of the Government of Canada, thus 
joining 45 countries, the World Health Organization (WHO), and more than 750 
organizations and associations around the world. The goal of this global effort is to raise 
awareness and take action on bone and joint disease and injury, improve the quality 
of life for people with musculoskeletal disorders and injury throughout the world, 
empower patients to participate in their own care, promote cost-effective prevention 
and treatment, and advance understanding of musculoskeletal disorders through 
research to improve prevention and treatment. These include joint disease, osteoporosis, 
osteoarthritis, low back pain, spinal disorders, severe trauma to the extremities, and 
crippling disease and deformities in children. As our population ages, the prevalence 
of many chronic bone and joint diseases and conditions will continue to increase 
consuming a far greater proportion of Canada’s health care resources. Chronic pain, 
loss of mobility and function, and loss of independence are common outcomes of a 
host of musculoskeletal and connective tissue conditions from osteoarthritis, systemic 
rheumatic diseases, osteoporosis and metabolic bone disorders to periodontal disease, 
fractures, and soft tissue injuries. The WHO estimates that several hundred million 
people already suffer from bone and joint disease and injuries around the world.
According to the Canadian Institutes of Health Research (CIHR) Institute of 
Musculoskeletal Health and Arthritis (May 2003), approximately 1.4 million Canadians 
are affected by osteoporosis, and this number is increasing as the population ages. 
By age 65 one in every two women will have osteoporosis, and by age 75, one in two 
will have experienced an osteoporotic fracture; and by age 90, one in three will have 
experienced a hip fracture (approximately twice the incidence rate in men). Women who 
have had an osteoporotic fracture are two to six times more likely to report difficulty 
in daily activities. Of those older people who experience a hip fracture, between 18% 
and 28% will die within a year of related complications. Total hip revision surgeries 
alone account for 25% of all implant surgeries after 15 years of implantation, or 30 000 
surgeries in Canada. Such a limited lifetime may be appropriate for the elderly who 
might not live beyond this timeframe, but for an aging active baby-boomer generation, 
this will not suffice. Although Canadian bone research is at the forefront of science and 
technology, these grim statistics speak to the complexity of this formidable challenge 
and to the limited success of current therapies. Indeed, musculoskeletal diseases 
rank second among the four most costly illnesses in Canada at C$17.8 billion/year 
(Arthroscope 1998). 
To outline the Canadian Regenerative Medicine and Nanomedicine Enterprise 
(CARMENE) (pronounced Carmen as in Georges Bizet’s French opera). I will begin 
by defining nanomedicine and the focus areas of interest to the Canadian research 
laboratories. I will then briefly discuss the current federal and provincial funding 
for CARMENE before closing with a description of the growing opportunities for 
nanomedicine businesses in Canada. International Journal of Nanomedicine 2006:1(3) 226
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Nanotechnology and nanomedicine
Nanoscience and nanotechnology refer to research and 
development of technologies at the atomic, molecular, or 
macromolecular levels – research where the characteristic 
dimensions are less than 100 nm. Nanotechnology research 
provides a fundamental understanding of phenomena and 
materials that enable the creation and use of structures, devices, 
and systems which have novel properties and functions 
because of their extremely small size. Nanotechnology 
has the potential to change radically the study of basic 
biological mechanisms, as well as to improve significantly 
the prevention, detection, diagnosis, and treatment of 
diseases and adverse medical conditions. The key to this 
potential is that nanotechnology operates at the same scale 
as biological processes, offering an entirely unique vantage 
point from which to view and manipulate fundamental 
biological pathways and processes. For instance, bone is 
a nanostructured composite material made up mainly of 
collagen Type I (a triple helix 300 nm in length and 0.5 nm 
in width) and hydroxyapatite crystals (50 nm long and 5 nm 
wide) within which bone cells are housed along with a host of 
other macromolecules. These components of bone that house/
interface with bone cells are organized from nanostructures 
creating a familiar milieu for bone cell activity.
Recent advances in the understanding of, and in the 
ability to manipulate, matter at this scale have resulted in 
new opportunities for research and technological change in 
almost every field of science and engineering. For instance, 
recent studies from our groups and elsewhere have shown 
that nanoscale surface topography can influence protein 
adsorption and determine cell morphology and physiology, 
cell shape, spreading, and cellular function such as cell growth, 
differentiation, gene expression, or metabolism. Recent 
studies have shown that patterning of biomolecules in a self-
assembled monolayer controls cell distribution, shape, and 
function most likely through the control of protein adhesion 
and cell behavior. It has become increasingly clear that bone 
cells do respond to nanofeatures but evidence for why and 
how they do so is still poorly documented. Nanotechnology 
provides the necessary tools at the required resolution for 
imaging, manipulation, and fabrication of nanofeatures 
similar to natural systems. It is thus possible, for instance, 
to systematically study and understand the mechanisms for 
bone cell response on nanostructured materials with tunable 
properties and architecture using both biochemical tools 
and physical techniques. An understanding of why and how 
cells respond to nanofeatures is very important in particular 
for the biomaterials and orthopedic communities because it 
offers new opportunities to engineer better implant surfaces 
for improved cell- and tissue-material interaction, and better 
tissue engineered materials for targeted drug delivery in 
musculoskeletal tissue.
Nanomedicine is a multidisciplinary field of research, 
requiring expertise in, and integration of, engineering, science, 
and medicine, balanced with a consideration of the social, 
cultural, and ethical impacts of these novel technologies 
with key rehabilitation and accessibility issues, as well as 
the potential economic costs of such treatments. A turning 
point in the history of Canadian nanomedicine was reached 
when the Canadian Institutes of Health Research (CIHR) 
(http://www.cihr-irsc.gc.ca) and their partners (Canadian 
Space Agency, ALS Society of Canada, Canadian Stroke 
Network of Canada, Heart and Stroke Foundation, Jacob’s 
Ladder, Juvenile Diabetes Research Foundation International, 
National Research Council of Canada, Natural Sciences 
and Engineering Research Council, NeuroScience Canada, 
Stem Cell Network, Ontario Neurotrauma Network) initiated 
the regenerative medicine and nanomedicine program in 
2003 (http://www.cihr-irsc.gc.ca/e/29542.html). In this 
context nanomedicine was defined as the design, synthesis, 
or application of materials, devices, or technologies in the 
nanometer-scale for the basic understanding, diagnosis, and/
or treatment of disease. The long-term goal of nanomedicine 
is to develop innovative and socially validated treatment 
approaches that will ultimately result in improved quality of 
life for afflicted individuals, populations, and their families. 
General areas of research currently pursued in Canada in 
this context include gene therapy, stem cell research, tissue 
engineering, and rehabilitation sciences. Specific applications 
of nanomedicine in Canada include (a) high resolution in-situ 
imaging, (b) nanoscale drug delivery systems, (c) ultrahigh-
throughput multiplexed screening using nanodevices or 
nanostructured materials, (d) integration of nanodevices with 
microfluidic systems for application in sensing, (e) single 
molecule detection, function, dynamics, and reactivity, (f) 
nanosystems biology, (g) ethical, legal, cultural, and social 
consequences of nanomedicine, as well as the potential 
economic costs associated with it. 
Funding nanotechnology in Canada
Since the implementation of the US national nanotechnology 
initiative with initial funding of over US$400 million in 2000, 
annual spending in nanotechnology has now reached US$750 
million in Japan, US$710 million in the US, US$335 million 
in Europe, and US$551 million in China, Korea, and Taiwan 
together. The Canadian government invested in education and 
research that resulted in major nanotechnology activities at 
most Canadian universities offering a PhD program in science International Journal of Nanomedicine 2006:1(3) 227
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and engineering, nine institutes of the National Research 
Council of Canada (National Institute for Nanotechnology, 
Biotechnology Research Institute, Industrial Materials 
Institute, Steacie Institute for Molecular Studies, Institute for 
Microstructural Sciences, Institute for Aerospace Research, 
Integrated Manufacturing Technologies Institute, Institute 
for Fuel Cell Innovation, Institute for National Measurement 
Standards), and a nanotechnology funding envelop for 
university research and infrastructure programs through 
CIHR, NSERC (http://www.nserc-crsng.gc.ca), CFI (Canada 
Foundation for Innovation, http://www.innovation.ca), and 
the Canadian Institute for Advanced Research (CIAR, http://
www.ciar.ca). Low cost tuition at major Canadian universities 
has created a highly educated talent pool. Funding for 
nanomedicine in particular was realized only recently through 
CIHR’s regenerative medicine and nanomedicine initiative 
(see previous section). The last round of NSERC’s Nano 
Innovation Platform Awards supported a good number of 
excellent, high-risk, high-gain projects in nanomedicine. 
At the provincial level, several initiative and networks are 
taking shape, such as the Advanced Systems Institute of 
British Columbia (http://www.bcinnovationcouncil.com/), 
or NanoQuébec (http://www.nanoquebec.ca) whose mission 
is to bring Québec to a leadership position in research 
and development of nanosciences and nanotechnologies 
nationally and internationally. The traditional provincial 
funding agencies such as the Alberta Energy Research 
Institute (AERI, http://www.aeri.ab.ca/) or the Alberta 
Agricultural Research Institute (AARI, http://www.aari.
ab.ca/) also support nanomedicine-related project on a smaller 
scale. Overall, while funding is flowing into the Canadian 
research laboratories, there is still no national nanotechnology 
initiative to coordinate, track, and champion the cause of 
nanomedicine. The scientific community knows, and the 
Canadian government is aware, that to be a global player in 
nanomedicine, it is necessary to create and support national/
provincial initiatives through competitive and organized 
provincial and federal funding. This is a unique opportunity, 
perhaps one of a kind in Canada, to shape the future of science 
and technology over the next few decades. 
Nanotechnology business in Canada
To help take nanomedicine to the next level, it is necessary to 
develop high-value added products that outperform current 
state-of-the-art. For instance, implantable materials, targeted 
drug delivery systems, and early detection technologies for 
disease markers and pathogens, are anticipated to provide 
the needed boost. Because of its vast wealth of natural 
resources, Canada is well positioned to be a major player 
in the commercialization of nanomedicine. Expertise, 
infrastructure, scientific environment, and technological 
clusters are key ingredient for the creation of nanobusinesses. 
Acceptance and integration of nanotechnologies particularly 
in nanomedicine will be a challenge for a number of reasons. 
Not only do they have to be approved by the regulatory 
agencies, but also their manufacturing may require significant 
technological and cultural adjustments on the part of the 
producers. According to the Canadian NanoBusiness 
Alliance (CNBA, http://www.nanobusiness.ca/), over 130 
organizations are currently involved in nanotechnology 
in Canada. Virtually all activities are conducted in the 
vicinity of five nanotechnology hubs (Edmonton, Montreal, 
Ottawa, Toronto, Vancouver). Some of the nanotechnology 
applications currently pursued include real time, remote 
sensing systems for chemicals and pathogens, implantable 
medical devices, tissue engineering, and drug delivery 
systems. 
Concluding notes
Finally, a few words about Bizet’s legendary opera Carmen, 
which was premiered at the Opéra Comique de Paris 
on March 3, 1875. For a year after its premiere, it was 
considered a failure, denounced by critics as “immoral” and 
“superficial”. Today, it is one of the world’s most popular 
operas. In fact, OPERA America (http://www.operaamerica.
org/) claims it to be the fourth most performed opera in North 
America. One may only hope that the fate of CARMENE 
will be that of Carmen. As is true for most paradigm-shifting 
research, it takes a few years for new ideas to take hold and 
for the research and development community to coalesce 
around those ideas and formulate thoughtful scientific 
plans. Nanoscale research has been percolating through the 
physical sciences and engineering communities for several 
years and has now reached the maturity to revolutionize 
medical research.
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